MARKET

ENLV

ENLV

Enlivex Therapeutics Ltd
NASDAQ
4.350
-0.040
-0.91%
Opening 12:24 10/05 EDT
OPEN
4.320
PREV CLOSE
4.390
HIGH
4.350
LOW
4.270
VOLUME
4.14K
TURNOVER
12.93K
52 WEEK HIGH
9.85
52 WEEK LOW
3.650
MARKET CAP
79.96M
P/E (TTM)
-3.0362
1D
5D
1M
3M
1Y
5Y
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the ...
GlobeNewswire · 2d ago
Enlivex to Present at Upcoming Investor and Media Conferences
Nes-Ziona, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will be presenting at the following inve...
GlobeNewswire · 09/13 12:00
BRIEF-Enlivex Announces New Preclinical Data In Murine Mesothelioma Model
BRIEF-Enlivex Announces New Preclinical Data In Murine Mesothelioma Model
Reuters · 09/12 13:40
Enlivex Highlights Presentation Of Preclinical Data In Murine Mesothelioma Model At ESMO Congress 2022
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a substantial and
Benzinga · 09/12 12:15
Enlivex to gets US patent covering use of cell therapy Allocetra
Enlivex Therapeutics (NASDAQ:ENLV) <a href="https://see...
Seekingalpha · 09/06 17:41
Enlivex Therapeutics Gets Notice of Allowance for US Patent Application for Allocetra; Shares Rise
Enlivex Therapeutics Gets Notice of Allowance for US Patent Application for Allocetra; Shares Rise
MT Newswires · 09/06 09:54
Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Enlivex Therapeutics (NASDAQ:ENLV) <a href="https://seekingalp...
Seekingalpha · 08/29 12:52
Enlivex Receives Notice Of Allowance For Japanese Patent Application Covering Allocetra Derived From Pooled Donor Cells
Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the &amp;ldquo, Company&amp;rdquo, )), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today
Benzinga · 08/29 12:10
More
About ENLV
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Webull offers kinds of Enlivex Therapeutics Ltd stock information, including NASDAQ:ENLV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENLV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENLV stock methods without spending real money on the virtual paper trading platform.